dystonia
Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations.
Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting <span class="disease" id="15389992-1-145-153">dystonia</span> with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous <span class="gene" id="15389992-1-248-252">GCH1</span> mutations.